Physician's Choice for Solid Tumors

"This clinical trial, monitored for a maximum of 30 months, is aiming to assess the Progression Free Survival (PFS) according to RECIST 1.1. As secondary objectives, it will evaluate Overall Survival (OS), Duration of Response (DOR) in both Part A and B when compared with physician's choice of treatment using RECIST 1.1 criteria as well; all outcomes are measured until disease progression or death occur or subsequent anticancer therapy begins."

"This clinical trial is active in 24 locations, including major cities such as Sioux Falls, Phoenix and Boston. It is advisable to choose the closest site so that travel can be kept to a minimum for those who are enrolled."

"Indeed, clinicaltrials.gov records suggest that this trial is still accepting patients since its inception on November 3rd 2020 and last update in August 1st 2022. 528 participants are required to be recruited across 24 different medical centres."

"Affirmative. According to information on clinicaltrials.gov, the trial initiated on 11/3/2020 and is actively seeking patient enrolments - with a total of 528 needed from 24 different medical centres."

"There exists some evidence that Physician's Choice is safe, so it was granted a score of 2. As this trial currently resides in Phase 2, there are yet to be any studies demonstrating its efficacy."

"At present, there are 7 live trials for Physician's Choice; none of which have yet to reach Phase 3. Most research sites are located in Salt Lake City, Utah however a total of 1765 locations globally are running studies on this medication."